2024-06-28
Big‑pharma‑AI partnerships are booming, yet large‑scale real‑world adoption of generative AI in drug discovery remains limited. Since 2015, 75 AI‑discovered molecules have entered clinical trials, dominated by oncology assets. These candidates deliver 80‑90% Phase 1 success rates (well above historical benchmarks), while Phase 2 performance (~40%) matches industry averages. Challenges persist in improving therapeutic efficacy, and no AI‑originated drug has gained market approval so far.